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randomized to either an early or late invasive strategy.
Total
Early
treatment
(n[71)
Late
treatment
(n[58) p-value RR (95% CI)
30 d follow-up
Combined incidence of
death, re-
infarction or
recurrent
ischemia (PEP)
8.9% 5.8% 12.7% .213 0.46 (0.14-1.48)
death 0% 0% 0% NA
MI 0% 0% 0% NA
recurrent ischemia 8.9% 5.8% 12.7% .213 0.46 (0.14-1.48)
Enzymatic infarct size
(single cardiac
TropT) ug/l med
(IQR)
0.27 (0.11-0.86) 0.27 (0.07-0.55) 0.27 (0.12-1.12) .100
bleeding 22.6% 26.1% 18.2% .296 1.44 (0.72-2.85)
major bleeding 12.1% 15.9% 7.3% .141 2.19 (0.74-6.51)
2 y follow-up
combined incidence of
death, re-
infarction or
recurrent
20.3% 18.8% 22.2% .644 0.85 (0.42-1.71)ACUTE CORONARY SYNDROME AND
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BACKGROUND Current guidelines deem percutaneous coronary
intervention (PCI) of a non-infarct related artery (n-IRA) at the time of
primary PCI (pPCI). This approach is being challenged by recent
studies, which show beneﬁts of complete rather than culprit vessel-
only revascularization at the time of pPCI. However, these studies
assessed grade of stenosis in the n-IRA by visual estimate. The impact
of fractional-ﬂow reserve (FFR) measurements during pPCI of n-IRA
has not been assessed.
METHODS COMPARE ACUTE is an ongoing prospective, randomized
strategy trial carried out at 22 sites across Europe and Asia. Patients
are randomly allocated (2:1) to receive either FFR guided multi-vessel
(MV) PCI vs. culprit vessel-only PCI with blinded FFR measurements
of n-IRA lesions in the setting of STEMI. The primary study endpoint
is MACCE deﬁned as death, myocardial infarction, any revasculari-
zation, or cerebral accident at 12 months. FFR measurements were
done directly after completion of pPCI in all n-IRA with visual esti-
mate of 50% stenosis. Positive FFR measurement was deﬁned
as 0.80 under maximal hyperemia.
RESULTS From July 2011 to April 2015, 728 STEMI patients undergo-
ing primary PCI with multi-vessel disease were enrolled. Mean age
was 62.0  10.4 (77.1% male) with Killip class I at presentation in
95.3%. In 37.3% the pPCI was performed in the LAD, 44.0% in the RCA
and 18.7% in the RCX. Successful pPCI deﬁned as TIMI 3 ﬂow was
achieved in 95.8%. FFR-measurements of 1000 n-IRA vessels (1023
lesions) were performed in the LAD in 40.1%, RCA 25.8% and RCX
34.1%. In 54% the FFR measurement of a n-IRA lesion was negative
and in 40% positive, 6% had no data available yet. On patient level
57% of the STEMI patients with angiographic multi-vessel disease had
no hemodynamic signiﬁcant lesions in the n-IRA.
CONCLUSIONS This preliminary data from the COMPARE ACUTE trial
indicates that a high portion of lesions found in non-infarct related
arteries with visual estimated stenosis of >50% are FFR negative. This
aspect should be taken into account during the debate on multi-vessel
primary PCI in STEMI patients.
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BACKGROUND Current guidelines recommend immediate revascu-
larization in patients with ST-segment elevation acute coronary
syndrome (STE-ACS). However, to date no evidence exists for
optimal treatment of ACS patients with initial ST elevation but
normalization of ST-segment elevation and anginal symptoms
before revascularization (transient ST-segment elevation or T-STE
ACS). We performed a pre-deﬁned subgroup analysis of the ELISA-3
trial to evaluate incidence and characteristics of patients with
T-STE ACS and to compare outcome of an early to a late invasive
strategy.
METHODS The ELISA-3 study is a prospective, multicentre trial in
which 542 patients hospitalized with high risk NSTE-ACS were ran-
domized to either an early (angiography and revascularization if
appropriate < 12h) or late invasive strategy (>48 h after randomiza-
tion). All patients were treated according to the guidelines. Incidence
and characteristics of patients with T-STE ACS were investigated and
effect of an early to a late invasive strategy in terms of combined
incidence of death, reinfarction and/or recurrent ischemia after 30
days and 2 years follow-up was compared.
RESULTS Transient ST elevation was seen in 129 (24.2%) patients
before randomization. In patients with T-STE, mean age was lower
(67.6 vs 71.4 y) and GRACE RISK score higher (142 vs 134). Incidence of
the composite endpoint after 30 days did not differ signiﬁcantly, but
was lower after 2 years follow-up in patients with T-STE ACS (20.3 vs
32.0%, p¼0.013), mainly driven by lower mortality (1.6 vs 9.5%
p¼0.004). No signiﬁcant interaction was found between T-STE and
treatment strategy on outcome. Within the group of patients with T-
STE ACS, early treatment showed a trend towards a lower incidence of
the combined endpoint after 30 days (5.8 vs 12.7%) and 2 years (18.8 vs
22.2%) follow up but these differences were not statistically signiﬁ-
cant (table 1). Enzymatic Infarct Size as assessed by a single cardiac
Troponin T, measured at 72-96 hours after admission or at discharge
was comparable.ischemia
death 1.6% 2.9% 0% .503 NA
MI 4.1% 4.3% 3.7% 1.00 1.17 (0.20-6.78)
recurrent ischemia 16.3% 14.5% 18.5% .548 0.78 (0.35-1.74)
PEP¼Primary End Point; IQR ¼ Inter Quartile Range
